Добірка наукової літератури з теми "Bifidobacterium infantis"
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "Bifidobacterium infantis".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Статті в журналах з теми "Bifidobacterium infantis"
1
Sakurai, Takuma, Toshitaka Odamaki, and Jin-zhong Xiao. "Production of Indole-3-Lactic Acid by Bifidobacterium Strains Isolated fromHuman Infants." Microorganisms 7, no. 9 (September 11, 2019): 340. http://dx.doi.org/10.3390/microorganisms7090340.
Повний текст джерелаАнотація:
Recent studies have shown that metabolites produced by microbes can be considered as mediators of host-microbial interactions. In this study, we examined the production of tryptophan metabolites by Bifidobacterium strains found in the gastrointestinal tracts of humans and other animals. Indole-3-lactic acid (ILA) was the only tryptophan metabolite produced in bifidobacteria culture supernatants. No others, including indole-3-propionic acid, indole-3-acetic acid, and indole-3-aldehyde, were produced. Strains of bifidobacterial species commonly isolated from the intestines of human infants, such as Bifidobacterium longum subsp. longum, Bifidobacterium longum subsp. infantis, Bifidobacterium breve, and Bifidobacterium bifidum, produced higher levels of ILA than did strains of other species. These results imply that infant-type bifidobacteria might play a specific role in host–microbial cross-talk by producing ILA in human infants.
2
Chen, Yuan Yao, Xin Zhao, Wolfgang Moeder, Hein M. Tun, Elinor Simons, Piushkumar J. Mandhane, Theo J. Moraes, et al. "Impact of Maternal Intrapartum Antibiotics, and Caesarean Section with and without Labour on Bifidobacterium and Other Infant Gut Microbiota." Microorganisms 9, no. 9 (August 31, 2021): 1847. http://dx.doi.org/10.3390/microorganisms9091847.
Повний текст джерелаАнотація:
Background and Aims: Few studies consider the joint effect of multiple factors related to birth, delivery mode, intrapartum antibiotic prophylaxis and the onset of labour, on the abundance of Bifidobacterium and the quantity of this genus and its species Bifidobacterium longum subsp. infantis in the infant gut microbiota. We implemented such a study. Methods: Among 1654 Canadian full-term infants, the gut microbiota of faecal samples collected at 3 months were profiled by 16S rRNA sequencing; the genus Bifidobacterium and Bifidobacterium longum subsp. infantis were quantified by qPCR. Associations between Bifidobacterium and other gut microbiota were examined by Spearman’s rank correlation. Results: Following vaginal birth, maternal IAP exposure was associated with reduced absolute quantities of bifidobacteria among vaginally delivered infants (6.80 vs. 7.14 log10 (gene-copies/g faeces), p < 0.05), as well as their lowered abundance relative to other gut microbiota. IAP differences in infant gut bifidobacterial quantity were independent of maternal pre-pregnancy body-mass-index (BMI), and remarkably, they were limited to breastfed infants. Pre-pregnancy BMI adjustment revealed negative associations between absolute quantities of bifidobacteria and CS with or without labour in non-breastfed infants, and CS with labour in exclusively breastfed infants. Significant correlations between Bifidobacterium abundance and other microbial taxa were observed. Conclusions: This study documented the impact of the birth mode and feeding status on the abundance of gut Bifidobacterium, and pointed to the important ecological role of the genus Bifidobacterium in gut microbiota due to its strong interaction with other gut microbiota in early infancy.
3
Young, Sarah L., Mary A. Simon, Margaret A. Baird, Gerald W. Tannock, Rodrigo Bibiloni, Kate Spencely, Juliette M. Lane, et al. "Bifidobacterial Species Differentially Affect Expression of Cell Surface Markers and Cytokines of Dendritic Cells Harvested from Cord Blood." Clinical Diagnostic Laboratory Immunology 11, no. 4 (July 2004): 686–90. http://dx.doi.org/10.1128/cdli.11.4.686-690.2004.
Повний текст джерелаАнотація:
ABSTRACT The gut microbiota may be important in the postnatal development of the immune system and hence may influence the prevalence of atopic diseases. Bifidobacteria are the most numerous bacteria in the guts of infants, and the presence or absence of certain species could be important in determining the geographic incidence of atopic diseases. We compared the fecal populations of bifidobacteria from children aged 25 to 35 days in Ghana (which has a low prevalence of atopy), New Zealand, and the United Kingdom (high-prevalence countries). Natal origin influenced the detection of bifidobacterial species in that fecal samples from Ghana almost all contained Bifidobacterium infantis whereas those of the other children did not. Choosing species on the basis of our bacteriological results, we tested bifidobacterial preparations for their effects on cell surface markers and cytokine production by dendritic cells harvested from cord blood. Species-specific effects on the expression of the dendritic-cell activation marker CD83 and the production of interleukin-10 (IL-10) were observed. Whereas CD83 expression was increased and IL-10 production was induced by Bifidobacterium bifidum, Bifidobacterium longum, and Bifidobacterium pseudocatenulatum, B. infantis failed to produce these effects. We concluded that B. infantis does not trigger the activation of dendritic cells to the degree necessary to initiate an immune response but that B. bifidum, B. longum, and B. pseudocatenulatum induce a Th2-driven immune response. A hypothesis is presented to link our observations to the prevalence of atopic diseases in different countries.
4
Sakurai, T., A. Yamada, N. Hashikura, T. Odamaki, and J. Z. Xiao. "Degradation of food-derived opioid peptides by bifidobacteria." Beneficial Microbes 9, no. 4 (June 15, 2018): 675–82. http://dx.doi.org/10.3920/bm2017.0165.
Повний текст джерелаАнотація:
Some food-derived opioid peptides have been reported to cause diseases, such as gastrointestinal inflammation, celiac disease, and mental disorders. Bifidobacterium is a major member of the dominant human gut microbiota, particularly in the gut of infants. In this study, we evaluated the potential of Bifidobacterium in the degradation of food-derived opioid peptides. All strains tested showed some level of dipeptidyl peptidase activity, which is thought to be involved in the degradation of food-derived opioid peptides. However, this activity was higher in bifidobacterial strains that are commonly found in the intestines of human infants, such as Bifidobacterium longum subsp. longum, B. longum subsp. infantis, Bifidobacterium breve and Bifidobacterium bifidum, than in those of other species, such as Bifidobacterium animalis and Bifidobacterium pseudolongum. In addition, some B. longum subsp. infantis and B. bifidum strains showed degradative activity in food-derived opioid peptides such as human and bovine milk-derived casomorphin-7 and wheat gluten-derived gliadorphin-7. A further screening of B. bifidum strains revealed some bifidobacterial strains that could degrade all three peptides. Our results revealed the potential of Bifidobacterium species in the degradation of food-derived opioid peptides, particularly for species commonly found in the intestine of infants. Selected strains of B. longum subsp. infantis and B. bifidum with high degradative capabilities can be used as probiotic microorganisms to eliminate food-derived opioid peptides and contribute to host health.
5
Hiraku, Akari, Setsuko Nakata, Mai Murata, Chendong Xu, Natsumi Mutoh, Satoshi Arai, Toshitaka Odamaki, et al. "Early Probiotic Supplementation of Healthy Term Infants with Bifidobacterium longum subsp. infantis M-63 Is Safe and Leads to the Development of Bifidobacterium-Predominant Gut Microbiota: A Double-Blind, Placebo-Controlled Trial." Nutrients 15, no. 6 (March 14, 2023): 1402. http://dx.doi.org/10.3390/nu15061402.
Повний текст джерелаАнотація:
Bifidobacteria are important intestinal bacteria that provide a variety of health benefits in infants. We investigated the efficacy and safety of Bifidobacterium longum subsp. infantis (B. infantis) M-63 in healthy infants in a double-blind, randomized, placebo-controlled trial. Healthy term infants were given B. infantis M-63 (n = 56; 1 × 109 CFU/day) or placebo (n = 54) from postnatal age ≤ 7 days to 3 months. Fecal samples were collected, and fecal microbiota, stool pH, short-chain fatty acids, and immune substances were analyzed. Supplementation with B. infantis M-63 significantly increased the relative abundance of Bifidobacterium compared with the placebo group, with a positive correlation with the frequency of breastfeeding. Supplementation with B. infantis M-63 led to decreased stool pH and increased levels of acetic acid and IgA in the stool at 1 month of age compared with the placebo group. There was a decreased frequency of defecation and watery stools in the probiotic group. No adverse events related to test foods were observed. These results indicate that early supplementation with B. infantis M-63 is well tolerated and contributes to the development of Bifidobacterium-predominant gut microbiota during a critical developmental phase in term infants.
6
Pozo-Rubio, T., J. R. Mujico, A. Marcos, E. Puertollano, I. Nadal, Y. Sanz, and E. Nova. "Immunostimulatory effect of faecal Bifidobacterium species of breast-fed and formula-fed infants in a peripheral blood mononuclear cell/Caco-2 co-culture system." British Journal of Nutrition 106, no. 8 (May 31, 2011): 1216–23. http://dx.doi.org/10.1017/s0007114511001656.
Повний текст джерелаАнотація:
Bifidobacterium spp. typical of the human intestinal microbiota are believed to influence the balance of immune responses in the intestinal mucosa. The aim of the present study was to investigate the effect of different bifidobacterial species and their mixtures in in vitro experiments with peripheral blood mononuclear cells (PBMC) and Caco-2 cells. Bifidobacterium adolescentis, B. angulatum, B. breve, B. catenulatum, B. infantis, B. longum and two combinations of these bifidobacteria simulating the species composition found in faecal samples from breast-fed (BF) and formula-fed (FF) infants were used. The levels of several cytokines were measured by direct stimulation of PBMC and by stimulation of a Caco-2/PBMC co-culture with bifidobacteria. B. catenulatum and B. breve were the strongest enhancers of interferon-γ (IFN-γ) production by direct stimulation of PBMC. B. longum was the highest inducer of IL-10 and the lowest TNF-α stimulus. In the Caco-2/PBMC system, B. breve was the highest inducer of IL-8 production by Caco-2 cells, significantly different from B. infantis, B. adolescentis and the FF mixture (P < 0·05). IFN-γ produced by PBMC stimulated with the BF mixture (containing 22 % B. breve, compared with 7 % in the FF mixture) was significantly higher compared with B. adolescentis, B. infantis and B. longum. B. adolescentis also inhibited IFN-γ production compared with the FF mixture and B. longum. The proportion of different Bifidobacterium strains seems to be an important determinant of the cytokine balance in the simulated intestinal environment studied. B. breve and the combination of the Bifidobacterium species typically found in the microbiota of BF infants have shown the most significant effects.
7
Hilliard, Margaret A., and David A. Sela. "Transmission and Persistence of Infant Gut-Associated Bifidobacteria." Microorganisms 12, no. 5 (April 27, 2024): 879. http://dx.doi.org/10.3390/microorganisms12050879.
Повний текст джерелаАнотація:
Bifidobacterium infantis are the primary colonizers of the infant gut, yet scientific research addressing the transmission of the genus Bifidobacterium to infants remains incomplete. This review examines microbial reservoirs of infant-type Bifidobacterium that potentially contribute to infant gut colonization. Accordingly, strain inheritance from mother to infant via the fecal-oral route is likely contingent on the bifidobacterial strain and phenotype, whereas transmission via the vaginal microbiota may be restricted to Bifidobacterium breve. Additional reservoirs include breastmilk, horizontal transfer from the environment, and potentially in utero transfer. Given that diet is a strong predictor of Bifidobacterium colonization in early life and the absence of Bifidobacterium is observed regardless of breastfeeding, it is likely that additional factors are responsible for bifidobacterial colonization early in life.
8
Taft, Diana H., Zachery T. Lewis, Nhu Nguyen, Steve Ho, Chad Masarweh, Vanessa Dunne-Castagna, Daniel J. Tancredi, et al. "Bifidobacterium Species Colonization in Infancy: A Global Cross-Sectional Comparison by Population History of Breastfeeding." Nutrients 14, no. 7 (March 29, 2022): 1423. http://dx.doi.org/10.3390/nu14071423.
Повний текст джерелаАнотація:
Bifidobacterium species are beneficial and dominant members of the breastfed infant gut microbiome; however, their health benefits are partially species-dependent. Here, we characterize the species and subspecies of Bifidobacterium in breastfed infants around the world to consider the potential impact of a historic dietary shift on the disappearance of B. longum subsp. infantis in some populations. Across populations, three distinct patterns of Bifidobacterium colonization emerged: (1) The dominance of Bifidobacterium longum subspecies infantis, (2) prevalent Bifidobacterium of multiple species, and (3) the frequent absence of any Bifidobacterium. These patterns appear related to a country’s history of breastfeeding, with infants in countries with historically high rates of long-duration breastfeeding more likely to be colonized by B. longum subspecies infantis compared with infants in countries with histories of shorter-duration breastfeeding. In addition, the timing of infant colonization with B. longum subsp. infantis is consistent with horizontal transmission of this subspecies, rather than the vertical transmission previously reported for other Bifidobacterium species. These findings highlight the need to consider historical and cultural influences on the prevalence of gut commensals and the need to understand epidemiological transmission patterns of Bifidobacterium and other major commensals.
9
Peirotén, A., J. L. Arqués, M. Medina, and E. Rodríguez-Mínguez. "Bifidobacterial strains shared by mother and child as source of probiotics." Beneficial Microbes 9, no. 2 (February 27, 2018): 231–38. http://dx.doi.org/10.3920/bm2017.0133.
Повний текст джерелаАнотація:
Importance of bifidobacteria as part of the infant intestinal microbiota has been highlighted. Their acquisition is influenced by the mode of birth and the feed regime afterwards, with a special role of the maternal microbiota. The presence of the same shared bifidobacterial strains between breast milk and infant faeces in 14 mother-infant pairs was assessed by means of pulsed-field gel electrophoresis (PFGE) genotyping. Four shared strains of Bifidobacterium breve (2), Bifidobacterium longum subsp. infantis and B. longum subsp. longum were found in breast milk-infant faeces pairs. Two years later, a second survey yielded four shared strains of the species Bifidobacterium adolescentis, Bifidobacterium bifidum, B. longum subsp. longum and Bifidobacterium pseudocatenulatum. Moreover, a B. bifidum strain was found to be shared by the infant faeces of the first study and the mother faeces tested two years later, pointing out a long term persistence. Some of the selected bifidobacterial strains showed probiotic potential due to their survival to gastrointestinal conditions and their ability to form biofilms.
10
Haarman, Monique, and Jan Knol. "Quantitative Real-Time PCR Assays To Identify and Quantify Fecal Bifidobacterium Species in Infants Receiving a Prebiotic Infant Formula." Applied and Environmental Microbiology 71, no. 5 (May 2005): 2318–24. http://dx.doi.org/10.1128/aem.71.5.2318-2324.2005.
Повний текст джерелаАнотація:
ABSTRACT A healthy intestinal microbiota is considered to be important for priming of the infants' mucosal and systemic immunity. Breast-fed infants typically have an intestinal microbiota dominated by different Bifidobacterium species. It has been described that allergic infants have different levels of specific Bifidobacterium species than healthy infants. For the accurate quantification of Bifidobacterium adolescentis, Bifidobacterium angulatum, Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium catenulatum, Bifidobacterium dentium, Bifidobacterium infantis, and Bifidobacterium longum in fecal samples, duplex 5′ nuclease assays were developed. The assays, targeting rRNA gene intergenic spacer regions, were validated and compared with conventional PCR and fluorescent in situ hybridization methods. The 5′ nuclease assays were subsequently used to determine the relative amounts of different Bifidobacterium species in fecal samples from infants receiving a standard formula or a standard formula supplemented with galacto- and fructo-oligosaccharides (OSF). A breast-fed group was studied in parallel as a reference. The results showed a significant increase in the total amount of fecal bifidobacteria (54.8% ± 9.8% to 73.4% ± 4.0%) in infants receiving the prebiotic formula (OSF), with a diversity of Bifidobacterium species similar to breast-fed infants. The intestinal microbiota of infants who received a standard formula seems to resemble a more adult-like distribution of bifidobacteria and contains relatively more B. catenulatum and B. adolescentis (2.71% ± 1.92% and 8.11% ± 4.12%, respectively, versus 0.15% ± 0.11% and 1.38% ± 0.98% for the OSF group). In conclusion, the specific prebiotic infant formula used induces a fecal microbiota that closely resembles the microbiota of breast-fed infants also at the level of the different Bifidobacterium species.
Дисертації з теми "Bifidobacterium infantis"
1
Gann, Reed N. "Host Signaling Response to Adhesion of Bifidobacterium infantis." DigitalCommons@USU, 2010. https://digitalcommons.usu.edu/etd/586.
Повний текст джерелаАнотація:
Investigations of the molecular binding partners of the probiotic bacterium Bifidobacterium longum subspecies infantis (B. infantis) and the pathogen Salmonella enterica subspecies enterica serovar Typhimurium LT2 (Salmonella ser. Typhimurium) found that these two very different bacteria bind gangliosides. However, these organisms lead to completely different host health outcomes when present in the gut. B. infantis is the founding microbial population in the intestinal tract of breast-fed infants. S. typhimurium is the most important food-borne pathogen that results in humans. This study used an in vitro gut epithelial cell model to examine the host cellular response to adhesion of B. infantis, which led to an increase in intestinal epithelium survival. This observation led to a series of experiments to elucidate the pathway for host signaling initiated by adherence of B. infantis to the host membrane to explain the increase in host cell survival. B. infantis adhesion induced significant (q≤0.05) differential expression of 208 host genes. These genes were associated with increased broad mechanisms of cell survival that included BIRC3, TNFAIP3, and SERPINB9. We hypothesized that a biochemical link existed between the host membrane adhesion protein and the increase in cell survival, mediated via AKT. We tested this hypothesis to demonstrate that B. infantis interaction initiated signal transduction using G-proteins via phosphorylation of AKT and induced production of the BIRC3, TNFAIP3, and SERPINB9. This study discovered adhesion of B. infantis initiated activation of AKT via phosphorylation of both Ser473 and Thr308, which results in increased cell survival.
2
Bahaka, Driss. "Analyse phenotypique et genotypique des souches du genre bifidobacterium appartenant ou apparentees aux especes b. Breve, b. Infantis et b. Longum." Lille 2, 1993. http://www.theses.fr/1993LIL2P254.
Повний текст джерела
3
Hung, Ming-Ni 1962. "Biochemical and genomic analysis of -galactosidases from Bifidobacterium infantis HL96." Thesis, McGill University, 2001. http://digitool.Library.McGill.CA:80/R/?func=dbin-jump-full&object_id=36953.
Повний текст джерелаАнотація:
Among 29 strains of bifidobacteria studied as sources of beta-galactosidase enzyme, Bifidobacterium infantis HL96 showed the highest hydrolytic and transgalactosylic activities. This strain grew well in a MRS medium containing various sugars including lactose, and produced three beta-galactosidases (termed beta-Gal I, II, III).Two genes, beta-galI and beta-galIII, located on 4.6 and 4.4 kb DNA fragments respectively, were cloned into E. coli, and the nucleotide sequences were determined. The 3,069 by-long beta-galI, encoded a polypeptide with a Mr of 113 kDa. A putative ribosome-binding site and a promoter sequence were recognized at the 5' flanking region of beta-galI. A partial sequence of an ORF transcribing divergently from beta-galI resembled a lactose permease gene. The beta-galIII gene, which is 2,076 bp long, encoded a polypeptide with a Mr of 76 kDa. A rho-independent, transcription terminator-like sequence was found 25 bp downstream of the termination codon.
The amino acid sequences of beta-GalI and beta-GalIII were homologous to those in the LacZ and LacG families, respectively. The acid-base, nucleophilic, and substrate recognition sites conserved in the LacZ family were found in beta-GalI, and a possible acid-base site proposed for the LacG family was located in beta-GalIII, containing a glutamate at residue 160. beta-GalI and beta-GalIII were over-expressed 35 and 96 times respectively in E. coli by using a pET expression system.
Both beta-GalI and beta-GalIII were specific for beta-D -anomeric linked galactosides, but beta-GalI showed more hydrolytic and synthetic activities toward lactose than beta-GalIII. The galacto-oligosaccharides (GaOS) production mediated by beta-GalI at 37°C in 20% (w/v) lactose was 130 mg/ml, which is six times higher than that of beta-GalIII. The yield of GaOS further increased to 190 mg/ml in 30% (w/v) lactose. A major tri-saccharide produced by beta-GalI was characterized as O-beta- D-galactopyranosyl-(1-3)-O-beta-D-galactopyranosyl-(1-4)- D-glucopyranose.
beta-GalI was purified by ammonium sulphate precipitation, and anion-exchange (Mono-Q) and gel filtration (Superose 12) chromatographic steps. The enzyme appeared to be a tetramer, with a Mr of 470 kDa as estimated by native PAGE and gel-filtration chromatography. The optimum temperature and pH for ONPG and lactose as substrates were 60°C, pH 7.5, and 50°C, pH 7.5, respectively. The enzyme was stable over the pH range of 5~8.5, and was particularly active at 50°C for more than 80 min. The enzyme was significantly activated by reducing agents, especially glutathione, as well as by Na+ and K+ cations. Maximal activity required both Na+ and K+ at a concentration of 10 mM. The enzyme was strongly inhibited by p-chloromercuribenzoic acid, and by most bivalent metal ions. Hydrolytic activity using 20 mM lactose as substrate was significantly inhibited by 10 mM galactose. The Km and Vmax values for ONPG and lactose were 2.6 mM, 262 U/mg, and 73.8 mM, 1.28 U/mg, respectively.
The objectives of this research were to characterize beta-galactosidases of B. infantis HL96 at the molecular and biochemical levels, and to over-express the enzymes in Escherichia coli. Two beta-galactosidase isoenzymes with unique properties were genetically characterized for the first time. beta-GalI properties included a neutral pH optimum, relatively higher temperature stability and a high transgalactosylic activity that makes it very competitive for GaOS synthesis. The results were also important for the advancement of knowledge on the catalytic mechanism and the evolutionary aspect of this enzyme.
4
Tu, Liwen. "Cloning and sequence analysis of multiple genes from Bifidobacterium infantis /." free to MU campus, to others for purchase, 2004. http://wwwlib.umi.com/cr/mo/fullcit?p3137758.
Повний текст джерела
5
Daigle, André. "Production d'un fromage à pâte ferme contenant des cellules vivantes de Bifidobacterium infantis." Thesis, National Library of Canada = Bibliothèque nationale du Canada, 1997. http://www.collectionscanada.ca/obj/s4/f2/dsk3/ftp05/mq25545.pdf.
Повний текст джерела
6
Sousa, Ana Lucia Orlandini Pilleggi de. "Viabilidade de Bifidobacterium animalis subsp. lactis HN019 em fórmulas infantis probióticas durante o armazenamento a 4 ºC." Universidade de São Paulo, 2011. http://www.teses.usp.br/teses/disponiveis/9/9133/tde-22082013-122441/.
Повний текст джерелаАнотація:
O objetivo deste trabalho foi estudar a viabilidade de Bifidobacterium animalis subsp. lactis HN019 em fórmulas infantis fermentadas ou não, probióticas durante armazenamento a 4°C. Três matrizes lácteas e três não lácteas (a base de soja) foram utilizadas para a elaboração de produtos fermentados ou não fermentados usando Bifidobacterium animalis subsp. lactis HN019, resultando em doze diferentes fórmulas probióticas para lactentes. O perfil de acidificação foi determinado a 42°C até pH 4,7. Determinações físico-químicas (sólidos totais, proteína, gordura, cinzas, carboidratos, calorias, densidade e pH) foram realizadas e foram focadas as contagens de bactérias viáveis durante o armazenamento refrigerado. A caracterização química dos produtos lácteos e a não lácteos apresentou resultados diferentes, à exceção FSL2, todos estavam de acordo com Codex Alimentarius. O perfil de acidificação de Bifidobacterium animalis subsp. lactis HN019 diferiu conforme a matriz. Durante o armazenamento dos produtos a 4°C, a contagem de bactérias viáveis de acordo com o preconizado, bem como a pós-acidificação, estando em conformidade com as recomendações da legislação brasileira. Processo (fermentação ou adição) e tipo de matriz (lácteos e não lácteos) influenciaram a pós-acidificação e a viabilidade de Bifidobacterium animalis subsp. lactis HN019. As fórmulas para lactentes podem ser considerados bons veículos de Bifidobacterium animalis subsp. lactis HN019.This study proposed to study infant formulas as vehicles for Bifidobacterium animalis ssp.lactis HNOI9. Three dairy and three non-dairy matrices were employed for the preparation of fermented or unfermented products using Bifidobacterium animalis ssp. lactis HN019 resulting in twelve different probiotic infant formulas. Acidification profile of the probiotic was determined at 42°C until pH 4.7. Physicochemical determination (total solids, protein, fat, ash, carbohydrates and calories, density and pH) was conducted, and counts viable bacteria (in dairy and non dairy infant formulas fermented and unfermented) during cold storage was focused on. The chemical characterization of the dairy and non-dairy matrix showed different results, the exception FSL2, all were in accordance to the Codex Alimentarius. The acidification profile of B. animalis ssp. lactis HN019 differed according to the matrix. During storage of products at 4°C counts of viable bacteria were stable as well as post-acidification, and were in accordance with the recommendations of the Brazilian legislation. Process (fermentation or addition) and matrix type (dairy and non-dairy) influenced post-acidification and viability of B. animalis ssp. lactis BN019 . Infant formulas could be considered good vehicles for Bifidobacterium animalis ssp. lactis HN019.
7
Yam, Godward Georgia Nga-Mun, of Western Sydney Hawkesbury University, Faculty of Science and Technology, and of Science Food and Horticulture School. "Studies on enhancing the viability and survival of probiotic bacteria in dairy foods through strain selection and microencapsulation." THESIS_FST_SFH_YamGodward_G.xml, 2000. http://handle.uws.edu.au:8081/1959.7/411.
Повний текст джерелаАнотація:
In this study, strains of probiotic bacteria have been selected for tolerance to low pH, bile, sucrose, oxygen in media and low storage temperatures. Lactobacillus acidophilus 2401 and Bifidobacterium infantis 1912 were selected as strains able to survive in these conditions. These two strains were then offered further protection from the adverse conditions of food processing and storage by microencapsulation in a calcium alginate and starch gel matrix. Encapsulation in calcium alginate increases survival in yoghurt. In cheddar cheese the free L. acidophilus 2401 and B. infantis 1912 cells survived better than the encapsulated cells, probably due to the dense nature of the cheddar cheese matrix combined with the encapsulation restricting the flow of the nutrients and metabolites between the outside environment and the cells. In ice cream survival was high, probably due to the high fat and solids nature of the ice cream combined with the low storage temperature. The trial results of the laboratory scale production was consistent with the survival results for yoghurt and cheddar cheese. Incorporation of encapsulated probiotic bacteria into ice cream and cheddar cheese was acceptable by sensory standards and largely unnoticeable in comparison with the same foods without capsules. The capsules were visible and able to be felt on the tongue when eaten in yoghurt causing the product to be disliked by the panellists.Master of Science (Hons)
8
Andrade, Samir de Deus Elian. "Efeitos da administração intragástrica de Bifidobacterium longum subsp. infantis CHCC2228 em um modelo murino agudo de colite ulcerativa induzida por sulfato sódico de dextrana (DSS)." Universidade Federal de Minas Gerais, 2013. http://hdl.handle.net/1843/BUOS-9KKHBA.
Повний текст джерелаАнотація:
IBDs are chronic inflammatory conditions, characterized by remissions and relapses, whose main manifestations are ulcerative colitis and Crohn's disease. Ulcerative colitis, one of the main forms of IBDS has as standard treatment the use of corticosteroids and anti-inflammatory drugs. The use of antibiotics has also been reported, but the possible adverse effects must be taken into consideration and thus the use of probiotics emerges as a real possibility. In this study, we evaluated the possibility of using Bifidobacterium longum subsp. infantis CHCC2228 as treatment for ulcerative colitis in a murine model. For induction of colitis in female BALB/c mice, we replace the water by a 3.5% DSS (dextran sodium sulphate) solution for 7 days. During this period, the animals were evaluated for weight variation, fecal consistency and presence of bleeding in feces. On the seventh day, the animals were euthanized to collect the organs to the histological analysis of the liver, small intestine and colon. Other experiments were done, as: dosage of sIgA in the small intestine; evaluation of the intestinal permeability; indirect evaluation of the infiltration of eosinophils, neutrophils and macrophages by measuring their specific enzymes EPO (eosinophil peroxidase), MPO (myeloperoxidase) and NAG (N-acetyl-glucosaminidase); dosage of the cytokines KC and Eotaxin-1; evaluation of the permeability and oxidative stress in the intestine. Treatment with the probiotic resulted in clinical improvement of animals. The histological and morphometric analyzes showed a reduction of lesions and edema in the animals, but there was no increase in the production of mucin. The dosage of sIgA was significantly higher in the colitis group and reduced in the group treated with the probiotic. There was also a reduction in the inflammation of the colon, as indicated by the reduction of EPO and MPO activity, but no change in the activity of NAG. The intestinal permeability, which is typically increased during the onset of IBD, was reduced after treatment with bifidobacteria. There were no differences on rates of reactive oxygen species (ROS) generation. Based on these data it can be concluded that the bacterium B. longum subsp. infantis CHCC2228 has probiotic potential for the treatment of ulcerative colitis, but further studies should be conducted in order to verify the mechanisms of action of the bacterium.Doenças inflamatórias intestinais (IBDs) são condições inflamatórias crônicas, marcadas por remissões e recidivas, de origem idiopática, mas que possuem mediação imunológica. A colite ulcerativa (UC), uma das principais formas de IBDs, tem como tratamento padrão o uso de anti-inflamatórios e corticosteróides. O uso de antibióticos também tem sido relatado, mas aqui devem ser considerados os efeitos colaterais associados. Nos últimos anos, a utilização de probióticos no tratamento de IBDs vem ganhando atenção na comunidade médica. Este trabalho objetivou avaliar os efeitos de Bifidobacterium longum subsp. infantis CHCC2228 no tratamento de UC em um modelo murino. Para a indução da colite em camundongos BALB/c fêmeas, a água foi suplementada com 3,5% de DSS (sulfato sódico de dextrana) a 3,5% por 7 dias. Durante este período os animais foram avaliados quanto à variação de peso, consistência fecal e presença de sangue nas fezes. No sétimo dia os animais foram eutanasiados para coleta dos órgãos para realização de análises histológica do fígado, do intestino delgado e do cólon. Foram, ainda, realizados: dosagem de imunoglobulina secretada (sIgA) no intestino delgado; avaliação da permeabilidade intestinal; avaliação indireta dos infiltrados de neutrófilos pela enzima mieloperoxidase (MPO), eosinófilos pela peroxidase eosinofílica (EPO) e macrófagos pela N-acetil-glicosaminidase (NAG); dosagem das citocinas KC e eotaxina-1; avaliação da permeabilidade e do estresse oxidativo no intestino. O tratamento com o probiótico melhorou o quadro clínico provocado pelo DSS nos animais. As análises histológicas e morfométricas mostraram que houve uma tendência à redução de áreas de lesão e edema nos animais, mas não houve aumento na produção de mucina. A dosagem de sIgA mostrou-se maior no grupo com colite e reduzido no grupo com colite e tratado com o probiótico. Houve, ainda, uma redução no quadro inflamatório do cólon, com redução das atividades enzimáticas de EPO e MPO, mas sem alteração na atividade de NAG. A permeabilidade intestinal, que está tipicamente aumentada durante o acometimento das IBD, mostrou-se reduzida após o tratamento com a bifidobactéria. Não foram observadas diferenças nas taxas de geração de espécies reativas de oxigênio (ROS). Baseado nestes dados pode-se concluir que a bactéria B. Longum subsp. infantis CHCC2228 possui potencial probiótico no modelo estudado e é um bom candidato para o tratamento para o tratamento da colite ulcerativa.
9
Yam, Godward Georgia Nga-Mun. "Studies on enhancing the viability and survival of probiotic bacteria in dairy foods through strain selection and microencapsulation." Thesis, View thesis View thesis, 2000. http://handle.uws.edu.au:8081/1959.7/411.
Повний текст джерелаАнотація:
In this study, strains of probiotic bacteria have been selected for tolerance to low pH, bile, sucrose, oxygen in media and low storage temperatures. Lactobacillus acidophilus 2401 and Bifidobacterium infantis 1912 were selected as strains able to survive in these conditions. These two strains were then offered further protection from the adverse conditions of food processing and storage by microencapsulation in a calcium alginate and starch gel matrix. Encapsulation in calcium alginate increases survival in yoghurt. In cheddar cheese the free L. acidophilus 2401 and B. infantis 1912 cells survived better than the encapsulated cells, probably due to the dense nature of the cheddar cheese matrix combined with the encapsulation restricting the flow of the nutrients and metabolites between the outside environment and the cells. In ice cream survival was high, probably due to the high fat and solids nature of the ice cream combined with the low storage temperature. The trial results of the laboratory scale production was consistent with the survival results for yoghurt and cheddar cheese. Incorporation of encapsulated probiotic bacteria into ice cream and cheddar cheese was acceptable by sensory standards and largely unnoticeable in comparison with the same foods without capsules. The capsules were visible and able to be felt on the tongue when eaten in yoghurt causing the product to be disliked by the panellists.
10
Watterlot, Laurie. "Analyse des effets de souches probiotiques anti-inflammatoires." Phd thesis, AgroParisTech, 2010. http://pastel.archives-ouvertes.fr/pastel-00570505.
Повний текст джерелаАнотація:
Les maladies inflammatoires chroniques de l'intestin sont caractérisées par une inflammation anormale et récurrente du tractus digestif. De nombreuses études ont démontré des effets bénéfiques de souches probiotiques anti-inflammatoires recombinantes ou non. La première partie de cette thèse décrit différentes stratégies d'optimisation de souches de bactéries lactiques en tant que vecteurs de protéines d'intérêt santé. Nous avons ainsi démontré qu'une modification du peptidoglycane de la paroie de Lactococcus lactis influençant la lyse bactérienne ne permettait pas de moduler l'immunogénicité de l'antigène E7 délivré par L. lactis. Nous avons également démontré que la nature du vecteur bactérien était un paramètre essentiel dans la vectorisation de la protéine délivrée : ainsi l'espèce Bifidobacterium infantis induit une réponse immunitaire spécifique à l'antigène E7 supérieure à celle obtenue avec les vecteurs L. lactis et Lactobacillus plantarum. La deuxième partie de cette thèse porte sur l'étude des effets anti-inflammatoires de bactéries recombinantes ou non. Nous avons ainsi démontré que la souche Lb. casei BL23 produisant une superoxyde dismutase à manganèse permettait de diminuer significativement des colites murines induites par administration de dextran sodium sulfate. Enfin, nous avons mis en évidence des propriétés anti-inflammatoires sur divers modèles d'inflammation in vitro / in vivo de Faecalibacterium prausnitzii, première bactérie commensale anti-inflammatoire identifiée sur la base de données cliniques humaines.
Книги з теми "Bifidobacterium infantis"
1
Cheng, Ronshan. Growth, physiological characteristics and plasmid profiles of Bifidobacterium species. 1989.
Знайти повний текст джерелаЧастини книг з теми "Bifidobacterium infantis"
1
Trujillo-de Santiago, G., and C. Rojas-de Gante. "Influence of Moisture Content and Temperature on the Stability of a Dehydrated Probiotic Dairy Product Containing Bifidobacterium infantis or Lactobacillus acidophilus." In Food Engineering Series, 461–68. New York, NY: Springer New York, 2015. http://dx.doi.org/10.1007/978-1-4939-2578-0_40.
Повний текст джерела
2
Lau, Amy Sie-Yik, Jin-Zhong Xiao, and Min-Tze Liong. "Bifidobacterium for Infants: Essence and Efficacy." In Microbiology Monographs, 39–72. Cham: Springer International Publishing, 2015. http://dx.doi.org/10.1007/978-3-319-23213-3_3.
Повний текст джерела
3
Farzini, Yusha, Mat Nor Rohana, and Abdul Khalil Khalilah. "Survivability characteristics of bifidobacterium spp. Isolates from newborn meconium and breast-fed/ formulated infant feces in acidic-simulated intestinal conditions." In Bioresources Technology in Sustainable Agriculture, 193–205. Waretown, NJ: Apple Academic Press, 2017.: Apple Academic Press, 2018. http://dx.doi.org/10.1201/9781315365961-14.
Повний текст джерела
4
"Bifidobacterium Infantis." In Hale’s Medications & Mothers’ Milk™ 2019. New York, NY: Springer Publishing Company, 2018. http://dx.doi.org/10.1891/9780826150356.0104.
Повний текст джерела
5
Quigley, E. M. M. "Bifidobacterium longum spp. infantis." In The Microbiota in Gastrointestinal Pathophysiology, 143–44. Elsevier, 2017. http://dx.doi.org/10.1016/b978-0-12-804024-9.00017-3.
Повний текст джерела
6
Ghatani, Kriti, Shankar Prasad Sha, Subarna Thapa, Priya Chakraborty, and Sagnik Sarkar. "Bifidobacterial Genome Editing for Potential Probiotic Development." In Genome Editing in Bacteria (Part 1), 62–87. BENTHAM SCIENCE PUBLISHERS, 2024. http://dx.doi.org/10.2174/9789815165678124010007.
Повний текст джерелаАнотація:
Genome editing is a promising tool in the era of modern biotechnology that can alter the DNA of many organisms. It is now extensively used in various industries to obtain the well-desired and enhanced characteristics to improve the yield and nutritional quality of products. The positive health attributes of Bifidobacteria, such as prevention of diarrhoea, reduction of ulcerative colitis, prevention of necrotizing enterocolitis, etc., have shown promising reports in many clinical trials. The potential use of Bifidobacteria as starter or adjunct cultures has become popular. Currently, Bifidobacterium bifidum, B. adolescentis, B. breve, B. infantis, B. longum, and B. lactis find a significant role in the development of probiotic fermented dairy products. However, Bifidobacteria, one of the first colonizers of the human GI tract and an indicator of the health status of an individual, has opened new avenues for research and, thereby, its application. Besides this, the GRAS/QPS (Generally Regarded as Safe/Qualified Presumption of Safety) status of Bifidobacteria makes it safe for use. They belong to the subgroup (which are the fermentative types that are primarily found in the natural cavities of humans and animals) of Actinomycetes. B. lactis has been used industrially in fermented foods, such as yogurt, cheese, beverages, sausages, infant formulas, and cereals. In the present book chapter, the authors tried to explore the origin, health attributes, and various genetic engineering tools for genome editing of Bifidobacteria for the development of starter culture for dairy and non-dairy industrial applications as well as probiotics.
7
Sancar Bozkurt, Hüseyin, and Havva Bozkurt. "Single Strain Probiotic Bifidobacteria Approach in Health and Non-Health Fields." In Prebiotics and Probiotics - From Food to Health [Working Title]. IntechOpen, 2021. http://dx.doi.org/10.5772/intechopen.99712.
Повний текст джерелаАнотація:
Single strain probiotic bifidobacteria approach is promising for the future in health and non-health fields. Recent studies show that intestinal lumen microbial content and tissue microbial content are different, so the personalized microbiome approach with the 16S rRNA analysis comes to the fore with the single strain probiotic bifidobacteria (BB-12,Infantis) approach. In addition to their immune modulation effect, they have beneficial effects such as preventing pathogens from binding to the intestinal mucosa via the biofilm layer they produce, and also their electrophysical properties in various atmospheric conditions, They have the ability to be used in non-health areas such as microplastic biodegradition, nanostructures, food and agriculture fields. The availability of single strain probiotic bifidobacteria in health, ecological and food systems are signs that progress in the single strain probiotic bacteria approach will be more accurate.
8
Lewis, Zachery T., and David A. Mills. "Differential Establishment of Bifidobacteria in the Breastfed Infant Gut." In Intestinal Microbiome: Functional Aspects in Health and Disease, 149–59. S. Karger AG, 2017. http://dx.doi.org/10.1159/000455399.
Повний текст джерела
9
Hack, Shirley, and Ari Bergwerk. "Lactose Intolerance." In Pediatric Nutrition In Chronic Diseases And Developmental Disorders, 340–45. Oxford University PressNew York, NY, 2005. http://dx.doi.org/10.1093/oso/9780195165647.003.0050.
Повний текст джерелаАнотація:
Abstract Lactose intolerance is a type of maldigestion in which a standard dose of lactose cannot be tolerated without developing biochemical changes. Symptoms of diarrhea, abdominal pain, bloating, and flatulence may also be present. Lactose intolerance is not an allergic reaction and should not be confused with milk protein allergy. It is the most common food intolerance and the most common carbohydrate malabsorption disorder. Lactose is the major carbohydrate source in the neonatal period. It is the preferred carbohydrate for infants, as it enhances the absorption of minerals such as calcium and magnesium, as well as the growth of lactobacilli and bifidobacteria in the intestinal tract Young children and adolescents continue to receive a significant amount of lactose in their diet from milk and milk products such as cheese and ice cream.
10
Gupta, Charu, Consuelo Pacheco, and Dhan Prakash. "Lactoserum." In Nutraceutical and Functional Foods in Disease Prevention, 432–56. IGI Global, 2019. http://dx.doi.org/10.4018/978-1-5225-3267-5.ch015.
Повний текст джерелаАнотація:
Lactoserum, a byproduct of cheese industry, is rich in nutrients, but it is discharged directly into the environment. It has many human applications that promise to be a complete nutraceutical for the future generations. It is of high nutritive value and its products can be used as functional ingredients in food and pharmaceutical applications and as nutrients in dietary and health foods. They contain full spectrum of amino acids including essential and branched-chain amino acids which are important in tissue growth and repair. The other biological activities of lactoserum are antibiotic, anti-cancer, anti-toxin, immune-enhancer, and prebiotic (growth enhancement of gut microflora such as bifidobacteria). Lactoserum can thus be used as nutraceutical in various products like infant formulas, food supplements, cheese spreads, sports bars, and beverages to meet a variety of health goals for people of all ages, including animal feed.
Тези доповідей конференцій з теми "Bifidobacterium infantis"
1
Smilowitz, Jennifer T., Melissa A. Breck, Jackelyn Moya, Annette Fineberg, and Mark Underwood. "Safety and Tolerability in Consuming Bifidobacterium Longum Subspecies Infantis in Exclusively Breastfed Term Infants." In Selection of Abstracts From NCE 2016. American Academy of Pediatrics, 2018. http://dx.doi.org/10.1542/peds.141.1_meetingabstract.559.
Повний текст джерела
2
Frese, Steven Alex, Andra Hutton, Lindsey Contreras, Claire Shaw, Jackelyn Moya, Melissa A. Breck, Annette Fineberg, Mark Underwood, and Jennifer T. Smilowitz. "The Imprint (infant Microbiota and Probiotic Intake) Study: Microbiome Remodeling in Breast-fed Term Infants Following Supplementation and Subsequent Colonization of a Keystone Bifidobacterium Species." In Selection of Abstracts From NCE 2016. American Academy of Pediatrics, 2018. http://dx.doi.org/10.1542/peds.141.1_meetingabstract.565.
Повний текст джерела
3
Louro, Beatriz Marques Barbosa, JÉSSICA MARTINS PIMENTA MIRANDA, NATHÁLIA TENÓRIO DE HOLANDA CABRAL COSTA, and YASMMYN DOS SANTOS REBOUÇAS. "ASPECTOS DA VIDA GESTACIONAL E NEONATAL E A DEFESA IMUNOLÓGICA DO RECÉM-NASCIDO." In II Congresso Brasileiro de Imunologia On-line. Revista Multidisciplinar em Saúde, 2022. http://dx.doi.org/10.51161/ii-conbrai/6208.
Повний текст джерелаАнотація:
Introdução: O sistema imunológico de um recém-nascido não se encontra integralmente desenvolvido, e tal imaturidade resulta em habilidades imunológicas ineficientes frente a possíveis patógenos nocivos à saúde do neonato. Sabe-se que a imunidade do bebê atravessa, então, um período de fragilidade durante a vida neonatal, no qual aspectos do meio vivenciado são importantes para uma defesa adequada em eventuais infecções, visto que estudos apontam influência de particularidades gestacionais e neonatais no anteparo imunológico de recém-nascidos, questão essencial para compreensão de cenários favoráveis à saúde infantil. Objetivos: O estudo traz como objetivo avaliar o envolvimento de aspectos da vida gestacional e neonatal na defesa imunológica do recém-nascido. Metodologia: Trata-se de revisão de estudos publicados, entre 2012 e 2022, nas plataformas Lilacs, Pubmed e Scielo, utilizando os descritores “imunidade”, “recém-nascidos” e “gestação”, incluindo estudos nos idiomas inglês e português. Resultados: A duração do período gestacional influencia na construção imunológica do neonato, uma vez que prematuros, devido ao inacabamento do extrato córneo da pele – camada externa importante na configuração desse órgão como barreira imunológica –, possuem maior chance de infecções. Ademais, uma adequada colonização da microbiota humana é essencial para modulação das respostas regulatórias do sistema imune, através de células como as Treg por exemplo, que, desajustadas, relacionam-se com doenças alérgicas e autoimunes. Sendo o parto o primeiro contato do neonato a microrganismos, um estudo observacional com amostras fecais de neonatos saudáveis evidenciou que o tipo de parto impacta a microbiota do recém-nascido, uma vez que aqueles nascidos por parto vaginal apresentaram, no mecônio, contagens bacterianas maiores, do que os nascidos por cesárea; como por exemplo, de espécies relacionadas com alergias quando diminuídas (dos gêneros Bifidobacterium e Lactobacillus). Ainda, cabe citar a presença no leite materno de anticorpos, principalmente IgA, essencial para a defesa das mucosas do neonato; sCD14, afetando a modulação das respostas imunes inatas e adaptativas; e componente secretor (CS) que bloqueia adesão epitelial, sendo importante na defesa contra patógenos. Conclusão: O recém-nascido, imunologicamente fragilizado, é influenciado por aspectos do meio a que é exposto na vida gestacional e neonatal, temática que deve ser abordada com gestantes, visando favorecer a saúde infantil.